Gene therapy company Genprex surged another 72% in premarket trading on Tuesday after soaring 263% on Monday. Genprex’s gene therapy trial progress are driving strong interest.

Last week, US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).

The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.

This latest move comes after the company completed the 0.09mg/kg dose group.

The SRC, consisting of three principal investigators, observed no dose-limiting toxicities in the current group and recommended the progression to the next dose level. The first patient in this portion of the trial experienced a partial remission, indicating the therapy’s potential clinical benefit.

Genprex president and CEO Ryan Confer said: “We believe the SRC’s recommendation to advance to the highest dose group of the Phase I portion of the trial is another clinical validation for our REQORSA development programme.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.